Robert Music, The Migraine Trust: Issues in the Diagnosis, Treatment and Access to Specialist Care for People with Migraine in the UK
We had the pleasure of meeting with Robert Music (Chief Executive of The Migraine Trust), to discuss a new report entitled: ‘State of the Migraine Nation, Dismissed for too long’, put together by The Migraine Trust. The report addresses the issues in the diagnosis, treatment and access to specialist care, and recommendations for improving migraine healthcare in the UK.
Please find Part 2 of the discussion here.
- Could you give us a brief overview of the health burden of migraine in the UK? (0:08)
- What sources of information were used to produce the State of the Migraine Nation report? (1:27)
- What problems were identified in terms of diagnosis, access to specialist care and new drugs? (2:33)
State of the Migraine Nation Dismissed for too long: Recommendations to improve migraine care in the UK
Disclosures: Robert Music has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!